Gemcitabin Hexal 200 mg/vial (IV Infusion)

200 mg vial: ৳ 975.00

Medicine Details

Category Details
Generic Gemcitabine
Company Sandoz a novartis division
Also available as
Gemcitabin hexal 1 gm injection

Title

Gemcitabin Hexal

Categories

  • Cytotoxic Chemotherapy

Indications

  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Breast Cancer
  • Ovarian Cancer

Pharmacology

  • Metabolism by nucleoside kinases
  • Inhibition of DNA synthesis
  • Induction of apoptosis

Dosage & Administration

  • Non-Small Cell Lung Cancer:
    • Single-agent Use
    • Combination Use
  • Pancreatic Cancer:
    • Weekly injections followed by a week of rest
  • Bladder Cancer:
    • Single agent use
    • Combination use
  • Breast Cancer:
    • Combination with Paclitaxel
  • Ovarian Cancer:
    • Combination with Carboplatin

Interaction

No confirmed interactions reported

Contraindications

  • Known hypersensitivity to Gemcitabine or any other components

Side Effects

  • Haematological Toxicity
  • Hepatic Toxicity
  • Gastrointestinal Effects
  • Genito-Urinary Toxicity
  • Pulmonary Toxicity
  • Allergic Toxicity
  • Neurotoxicity
  • Alopecia

Pregnancy & Lactation

Pregnancy Category D

Precautions & Warnings

  • Caution in patients with risk of toxicity
  • Hepatic Toxicity
  • Embryofetal Toxicity

Use in Special Populations

  • Elderly Patients
  • Renal and Hepatic Impairment
  • Children

Overdose Effects

No known antidote

Storage Conditions

Store at 20°C to 25°C, away from light

Dimensions

Standard vial sizes

Color Options

N/A

Materials

Glass vials, chemical components

Usability Features

  • Intravenous infusion
  • Use in combination therapy

Technical Specifications

  • Metabolism by nucleoside kinases
  • Inhibition of DNA synthesis
  • Induction of apoptosis

Design Elements

Standard pharmaceutical vial design

Functions

Cytotoxic chemotherapy for various cancers

Absorption Rate

N/A

Half-Life

Affected by age

Dosage Forms

Intravenous infusion

Age Group

  • Elderly Patients
  • Children

Hazardous Properties

Cytotoxicity

Toxicity Levels

  • Mild to moderate myelosuppression

Efficacy

Treatment of various types of cancer

Safety Features

Monitoring for toxicity, supportive therapy for overdose

Clinical Trials

Limited Phase I and II trials in children

Efficacy Studies

Combination therapy for metastatic breast cancer

Chemical Composition

Gemcitabine

Patient Monitoring

Blood counts, renal function

Adverse Reactions

Anaemia, leukopenia, thrombocytopenia, hepatic abnormalities, gastrointestinal effects, genito-urinary effects, pulmonary effects, allergic reactions, neurotoxicity, alopecia

Dosage Reduction

Based on toxicity experienced by the patient

Aetiology

Of renal failure

Drug Class

Cytotoxic Chemotherapy

Storage Precautions

Do not refrigerate as crystallisation may occur

Child Safety

Keep out of the reach of children

Related Brands